Sugi Predict

Sugi Predict / Targets / UGT2B7

UGT2B7

UDP-glucuronosyltransferase 2B7 · P16662 · UGT2B7 on Sugi Atlas →

8,198 patent compounds predicted against UGT2B7, 4,349 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL956391 SCHEMBL956391 0.51 8/20
SCHEMBL956392 SCHEMBL956392 0.51 8/20
SCHEMBL1105231 SCHEMBL1105231 0.43 7/20
SCHEMBL954542 SCHEMBL954542 0.52 5/20
SCHEMBL954543 SCHEMBL954543 0.52 5/20
SCHEMBL954950 SCHEMBL954950 0.52 5/20
SCHEMBL954951 SCHEMBL954951 0.52 5/20
SCHEMBL385019 SCHEMBL385019 0.41 5/20
SCHEMBL541382 SCHEMBL541382 0.32 4/20
SCHEMBL954794 SCHEMBL954794 0.38 2/20
SCHEMBL954796 SCHEMBL954796 0.38 2/20
SCHEMBL420093 SCHEMBL420093 0.37 2/20
SCHEMBL1245653 SCHEMBL1245653 0.35 2/20
SCHEMBL38049 SCHEMBL38049 0.35 2/20
SCHEMBL38050 SCHEMBL38050 0.35 2/20
SCHEMBL221714 SCHEMBL221714 0.34 2/20
SCHEMBL642122 SCHEMBL642122 0.34 2/20
SCHEMBL791541 SCHEMBL791541 0.34 2/20
SCHEMBL1008583 SCHEMBL1008583 0.34 2/20
SCHEMBL1122750 SCHEMBL1122750 0.34 2/20

Clinical trials — most relevant to UGT2B7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cholestatic Drug-induced Liver Injury PHASE4UNKNOWN
Effect of Genetic Polymorphisms of UGT on the PKs of Indapamide in Egyptians PHASE4UNKNOWN
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies PHASE4RECRUITING
Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial PHASE3UNKNOWN
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer PHASE3COMPLETED
CBD for Pain Following Orthopedic Shoulder Surgery PHASE1/PHASE2RECRUITING
Oral Cannabidiol for Opioid Withdrawal PHASE1/PHASE2COMPLETED
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer PHASE2COMPLETED
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer PHASE2UNKNOWN
Paclitaxel and Irinotecan in Advanced Gastric Cancer PHASE1/PHASE2COMPLETED
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors PHASE1COMPLETED
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours PHASE1UNKNOWN
Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Pharmacokinetic Profile of OROS Hydromorphone in Healthy Taiwanese Participants With Different Genotypes for the UGT2B7 Gene PHASE1COMPLETED
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors PHASE1UNKNOWN
Study of NK012 in Patients With Refractory Solid Tumors PHASE1COMPLETED
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes PHASE1RECRUITING
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors PHASE1COMPLETED
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin PHASE1COMPLETED
A Research Study on Etavopivat in Participants With and Without Liver Disease PHASE1COMPLETED
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors PHASE1COMPLETED
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060 PHASE1COMPLETED
OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma PHASE1COMPLETED
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma PHASE1COMPLETED
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac EARLY_PHASE1RECRUITING
Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype nanUNKNOWN
Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C nanCOMPLETED
Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI nanCOMPLETED
Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a UGT2B7 binder may also engage these)

ProteinNameSimilarity
Q9TSL6 — 1.000 Q9TSL6 →
P19488 — 1.000 P19488 →
Q5RFJ3 — 1.000 Q5RFJ3 →
O19103 — 1.000 O19103 →
Q80X89 — 1.000 Q80X89 →
O02663 — 1.000 O02663 →
P36513 — 1.000 P36513 →
P54855 — 1.000 P54855 →
P09875 — 1.000 P09875 →
UGT2B17 UDP-glucuronosyltransferase 2B17 1.000 landscape →
Q6UWM9 — 1.000 Q6UWM9 →
Q62789 — 0.999 Q62789 →
Q9XT55 — 0.999 Q9XT55 →
O75310 — 0.999 O75310 →
Q6PDD0 — 0.999 Q6PDD0 →
O77649 — 0.998 O77649 →
O97951 — 0.998 O97951 →
Q9GLD9 — 0.998 Q9GLD9 →
Q6K1J1 — 0.997 Q6K1J1 →
P08541 — 0.997 P08541 →
P17717 — 0.997 P17717 →
P36537 — 0.997 P36537 →
P06133 — 0.997 P06133 →
Q8WN97 — 0.997 Q8WN97 →
P36510 — 0.997 P36510 →
Q8BWQ1 — 0.997 Q8BWQ1 →
P36511 — 0.996 P36511 →
P36512 — 0.995 P36512 →
Q9R110 — 0.995 Q9R110 →
P0DTE5 — 0.995 P0DTE5 →